Literature DB >> 17295029

Thrombotic microangiopathy and intravenous immunoglobulin therapy.

Toru Watanabe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17295029     DOI： 10.1007/s00467-007-0441-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  9 in total

Review 1.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin.

Authors:  A Ephrem; N Misra; G Hassan; S Dasgupta; S Delignat; J-P Duong Van Huyen; S Chamat; F Prost; S Lacroix-Desmazes; S V Kavery; M D Kazatchkine
Journal:  Clin Exp Med       Date:  2005-12       Impact factor: 3.984

2.  Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

Authors:  Marie-Agnès Dragon-Durey; Chantal Loirat; Sylvie Cloarec; Marie-Alice Macher; Jacques Blouin; Hubert Nivet; Laurence Weiss; Wolf Herman Fridman; Véronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2004-12-08       Impact factor: 10.121

Review 3.  Complement dysfunction in hemolytic uremic syndrome.

Authors:  Peter F Zipfel; Christine Skerka
Journal:  Curr Opin Rheumatol       Date:  2006-09       Impact factor: 5.006

4.  Intravenous gamma globulin for thrombotic microangiopathy of unknown etiology.

Authors:  Shuichi Ito; Kenichi Okuyama; Tomoko Nakamura; Jun-Ichi Tetanishi; Kazuo Saito; Masanori Matsumoto; Yoshihiro Fujimura; Yukoh Aihara; Shumpei Yokota
Journal:  Pediatr Nephrol       Date:  2006-10-21       Impact factor: 3.714

5.  Efficacy of intravenous immunoglobulin in the treatment of thrombotic thrombocytopaenic purpura. A study of 44 cases.

Authors:  J Dervenoulas; P Tsirigotis; G Bollas; A A Koumarianou; V Pappa; G Mantzios; N Xiros; T Economopoulos; E Papageorgiou; M Pappa; S A Raptis
Journal:  Acta Haematol       Date:  2001       Impact factor: 2.195

6.  The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts.

Authors:  V Fremeaux-Bacchi; E J Kemp; J A Goodship; M-A Dragon-Durey; L Strain; C Loirat; H-W Deng; T H J Goodship
Journal:  J Med Genet       Date:  2005-03-22       Impact factor: 6.318

Review 7.  The molecular biology of thrombotic microangiopathy.

Authors:  H-M Tsai
Journal:  Kidney Int       Date:  2006-05-31       Impact factor: 10.612

8.  Intravenous immunoglobulin protects against experimental thrombotic microangiopathy.

Authors:  J A Jefferson; S I Suga; Y G Kim; J Pippin; K L Gordon; R J Johnson; W G Couser
Journal:  Kidney Int       Date:  2001-09       Impact factor: 10.612

9.  Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Italian Cooperative Group for TTP.

Authors:  R Centurioni; E Bobbio-Pallavicini; C Porta; F Rodeghiero; L Gugliotta; A Billio; F Tacconi; E Ascari
Journal:  Haematologica       Date:  1995 Jul-Aug       Impact factor: 9.941
  9 in total
  1 in total

1.  Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.

Authors:  Jeffrey M Saland; Benjamin L Shneider; Jonathan S Bromberg; Patricia A Shi; Stephen C Ward; Margret S Magid; Corinne Benchimol; Mouin G Seikaly; Sukru H Emre; Elena Bresin; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2008-11-12       Impact factor: 8.237
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.